Supreme Court Critiques High Cancer Drug Prices as NPPA Cuts Generic Medicine Rates
The Supreme Court of India has criticized hospitals and regulatory bodies for excessive markups on cancer medicines, highlighting cases where patients were charged up to 100-200 times the procurement cost. The court questioned the government's pricing policies and called such practices 'dacoity.' In response, the National Pharmaceutical Pricing Authority (NPPA) has reduced retail prices for 543 cancer drug formulations by up to 93%, mainly affecting generics, while leaving many patented drugs' prices unchanged. The court is considering broader regulation of trade margins to improve affordability and access to essential medicines.
First-hand measurement across 14 sources
We measured how 14 outlets covered this story. Coverage leans balanced overall (Left 0%, Centre 64%, Right 36%). Overall sentiment is neutral (51/100). Lens Score 42/100.
Outlets measured: indiatoday, theprint, moneycontrol, economictimes, mint, hindustantimes, thestatesman, indiatoday, and 6 more. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
All 1 outlets scored close to centre on political lean. The real divergence here is in emphasis, not lean — compare the headlines below to see how each outlet chose to frame the same facts.
Sentiment ranged widely across outlets — from 32/100 to 75/100 — a sign the coverage itself was contested, not just reported.
Coverage timeline
economictimes broke this story on 25 Oct, 07:24 am. Other outlets followed.